Aristotle University Of Thessaloniki (AUTH)
Η επίδραση χορήγησης του συμπλόκου του μη - ιϊκού μεταφορέα DDMC με πλασμίδιο p53 σε πειραματικά προκαλούμενο καρκίνο του πνεύμονα: παθολογοανατομική και ανοσοϊστοχημική εκτίμηση ευρημάτων
Abstract
dc:descriptionIntroduction Recent advances in the detection of genetic alterations and the clarification of their role in pathogenesis of lung cancer led to the development of powerful and specific targeting therapies based on genetic and biochemical alterations, as well as promising new strategies, such as gene therapy. At present, the main goal in gene therapy is the development of a stable and non-toxic gene vector that can integrate and transfer efficiently genetic material to specific cells, such as cancer cells. Aim To evaluate the safety and efficacy of intratumoral and intravenous administration of non-viral DDMC vector conjugated with p53 plasmid in mice with developed Lewis Lung Carcinoma in comparison with the control group and to correlate the results based on histological and immunohistochemical findings. Material and Methods The study included 30 female mice (C57BL / 6), 7-8 weeks old, in which cancer cells of Lewis Lung Carcinoma cell line (ATCC-CRL-1642) were implanted subcutaneously to their back. The mice were divided into three groups: (a) controls, (b) intravenous and (c) intratumoral. The first group (controls) did not receive any treatment. In the second and third group the DDMC vector / p53 plasmid solution was injected intravenously or intratumorally, respectively, 2 times / week for 3 weeks. During the experiment, the tumor volume was measured once weekly. After the end of the experimental procedure, a necropsy was performed, while tissues and organs were collected. Histological examination and immunohistochemical analysis using p53, Ki-67 and CD34 antibodies on sections of formalin-fixed, paraffin-embedded tissues was followed. Results The results of intratumoral administration of non-viral vector DDMC conjugated with plasmid p53 (shRNA) showed increased mean survival (17.3 days) compared to the intravenous group (15.75 days) and the control group (12,6 days) (p= 0.029 <0.05) and reduced distant metastasis with presence of lung metastasis to 4/10 (40%) mice compared to the intravenous group (7/10 (70%)) and the control group (100%). In two subjects there were no lung metastasis after 20 and 21 days and six administrations. Macroscopical findings indicated that only in the control group lung metastasis were visible. Tumor growth rate was also controlled in the intratumoral group as well as extensive tumor necrosis was found (45.1%) in comparison to the intravenous group (25%) and the control group (22.9%) (p = 0.000 <0.05). In addition, there was lower expression of histochemical markers p53 and Ki-67 in tumor tissue in the same group (p = 0.034 <0.05 and p = 0.012 <0.05 respectively). No specific histopathological findings observed in the organs of a particular group. Conclusions The administration of non-viral DDMC vector conjuncted with plasmid p53 in mice with developed Lewis Lung Carcinoma seems to be a safe and well tolerated procedure irrespective of the management method (intravenous or intratumoral), while the intratumoral administration more efficiently presents local tumor and distant metastasis control. However, the ideal methodology still has to be investigated as several parameters have to be improved.
Degree
thesis:*- Grantor dc:publisher
- Aristotle University Of Thessaloniki (AUTH)
- Year dc:date
- 2018
Author and committee
dc:creator, dc:contributor.*- Authors dc:creator
-
- Baliaka, Aggeliki
- Μπαλιάκα, Αγγελική
Subjects
dc:subject × 16Rights
dc:rights- Statement dc:rights
-
- BY_NC_SA
- Language dc:language
- gre
Identifiers
dc:identifier.*- Identifier
- 10.12681/eadd/44544